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The development of contrast agents (CAs) for Magnetic Resonance Imaging (MRI) with T1-
T2 dual-mode relaxivity requires the accurate assembly of T1 and T2 magnetic centers in a 
single structure. In this context, we have synthesized a novel hybrid material by monitoring 
the formation of Prussian Blue analogue Gd(H2O)4[Fe(CN)6] nanoparticles with tailored 
shape (from nanocrosses to nanorods) and size, and further protection with a thin and 
homogeneous silica coating through hydrolysis and polymerization of silicate at neutral pH. 
The resulting Gd(H2O)4[Fe(CN)6]@SiO2 magnetic nanoparticles are very stable in 
biological fluids. Interestingly, this combination of Gd and Fe magnetic centers closely 
packed in the crystalline network promotes a magnetic synergistic effect, which results in 
significant improvement of longitudinal relaxivity with regards to soluble Gd3+ chelates, 
whilst keeping the high transversal relaxivity inherent to the iron component. As a 
consequence, this material shows excellent activity as MRI CA, improving positive and 
negative contrast in T1- and T2- weighted MR images, both in in vitro (e.g., phantom) and 
in vivo (e.g., Sprague-Dawley rats) models. In addition, this hybrid shows a high biosafety 
profile and has strong ability to incorporate organic molecules on surface with variable 
functionality, displaying great potential for further clinical application.  
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Magnetic resonance imaging (MRI) is a powerful and thoroughly used non-invasive and 
non-radioactive technique for clinical diagnostic that can provide information on the 
anatomy, function and metabolism of tissues in vivo.1-5 In 1H-MRI, Signal Intensity (SI) 
depends on a combination of factors including proton density, longitudinal (T1) and 
transversal (T2) relaxivity times and the microenvironment (cell density, pH, oxygenation). 
Unfortunately, the intrinsic contrast provided by these factors and associated changes due 
to a pathologic condition are often too limited to enable a sensitive and accurate diagnosis. 
For that reason, there is an increased use of MRI contrast agents (CA) that improve image 
resolution based on their selective accumulation in the Region Of Interest (ROI).6 Based on 
their relaxation activity, these CAs are classified as positive (T1-weighted) or negative (T2-
weighted) image contrast promoters. All clinically approved MRI T1 CAs are based on 
paramagnetic Gd3+ soluble chelates with polyamino-polycarboxylate ligands,7,8 due to their 
strong paramagnetic activity. However, the use of Gd3+ solutions involves some technical 
issues and health risks that limit imaging performance. Here, the quick renal filtration 
indicates a poor pharmacokinetic profile, reducing sensitivity, increasing scanning time, and 
imposing the administration of high Gd3+ doses,9 which may lead to toxicity effects, such 
as headache, nausea, dizziness and nephrogenic systemic fibrosis.10-12 On the other hand, 
current T2 CAs in clinical practice are based on superparamagnetic iron oxide nanoparticles 
(SPIONs),13 which produce T2 shortening, providing negative contrast. However, this is 
hardly seen in low signal body regions, and it may be confused with hemorrhages, 
calcification, fat, blood clots and other possible artifacts in damaged tissue, which lowers 





At this point, the acquisition of MRI weighted in  T1 and T2 could improve the safety of 
diagnosis and cross-validate the possible false-positive information.14 T1-T2 dual-modal 
strategy can provide complementary T1 and T2 MRI images, making it possible to isolate 
artifact signals from the contrast agents in the ROI.15  An ideal T1-T2 dual-modal MRI 
acquisition is desirable for tissues with moderate T1 and T2 relaxation times, such as liver, 
kidneys, muscle and brain matter.12 Actually, some nanoparticles present unique 
characteristics that allow exploiting the T1-T2 dual-mode CA concept. Several strategies 
have been proposed for the development of these materials. The simplest way is the direct 
conjugation of T1 elements (e.g., Gd or Mn-containing systems) and T2 elements (e.g., 
SPIONs). For instance, Gd-chelates can be covalently coupled over the surface of 
SPIONs,16 although this usually results in low gadolinium loading; not to mention the fact 
that metal leaching in physiological fluids may be an issue. Alternatively, a hybrid system 
of T1 and T2 elements can be prepared by assembling gadolinium oxide and iron 
nanoparticles in a core-shell layout structure.17 Unfortunately, interferences are usual, as 
magnetic coupling induced by close T2/T1 structures trends to undesirable quenching of both 
T2 and T1 signals in MRI.18 In these cases, a silica separating layer inserted between the T2 
magnetic nanoparticle (core) and the T1 contrast material (shell) allows for a fine separation 
distance control, which can minimize the perturbation of T2 signal over the T1 contrast 
effect.19 However, although the SiO2 layer between the T2 core and T1 shell may attenuate 
magnetic coupling, it also reduces the magnetic field to surrounding water molecules, 
leading to strong T2 signal reduction.20 Conversely, it is possible to minimize T1 and T2 
signal coupling by monitoring the incorporation of Gd3+ into iron nanoparticles. Here, 





by synthesis of “Janus” nanoparticles with both components,20 have shown improved 
magnetic properties, with a synergistic action between T1 and T2 centers that enhance 
contrast effects in MR imaging. Moreover, a similar cooperative effect has been reported 
by doping SPIONs with Mn2+ ions.22  
In this context, it has been reported that Prussian Blue (PB) analogues doped with Gd3+, 
with general molecular formula KxGd1-x(H2O)n[Fe(CN)6] and nanosized crystallites, may 
present high performance as dual T1-T2 contrast agents.23,24 In these materials, T1 and T2 
magnetic centers are located in the same crystalline framework, very close to each other. 
Also, Mn-doped PB has been proposed as CA with ultrahigh longitudinal relaxivity.25 The 
local magnetic field induced by the superparamagnetic Fe centers promotes Gd spins 
alignment in the same direction, resulting in a boost of T1 contrast effect21,26 which, gathered 
with the strong T2 contrast activity associated to Fe atoms, may promote a mastered 
combination of magnetic centers in the same network for dual-modal MRI. Unfortunately, 
and despite the good relaxivity results obtained in in vitro studies, the clinical use of PB 
derivatives as MRI CAs is precluded by their partial solubility in aqueous medium at 
physiological pH, releasing toxic quantities of both Gd and Fe ions. This situation, 
nevertheless, could be skipped if Gd-containing PB nanoparticles are protected with a stable 
and diamagnetic thin silica coating. This is not possible in alkaline medium, as PB and its 
analogs react with soluble silicate, triggering an ion exchange process which results in 
complete iron exchange and stoichiometric condensation of gadolinium hydroxide and 
silica, to give Gd(OH)3.3SiO2.xH2O composite.27,28 Herein, we have successfully carried 
out the coating of PB derivative Gd(H2O)4[Fe(CN)6] nanoparticles by polymerizing the 





developed by our group to activate silica at pH~7 by using functional mimics of the protein 
silicatein α (e.g., triethylamine, TEA)29 as catalyst. By stepwise control of 
Gd(H2O)4[Fe(CN)6] preparation and subsequent silane hydrolysis and polymerization, we 
have obtained hybrid material Gd(H2O)4[Fe(CN)6]@SiO2 nanoparticles, very stable in 
biological fluids, with tailored shape (from nanocrosses to nanorods) and size. By 
combining Gd and Fe magnetic centers closely packed in the same crystalline structure a 
magnetic synergistic effect is imposed by Fe atoms over Gd sites, which leads to strong 
increase of longitudinal relaxivity, whilst keeping the high transversal relaxivity 
corresponding to Fe centers. This results in a CA with constant Gd:Fe atomic ratio able to 
improve positive and negative contrast in T1- and T2- weighted MR images, both in in vitro 
(e.g., phantom) and in vivo (e.g., Sprague-Dawley rats) systems. Furthermore, this material 
shows low cytotoxicity in cell culture studies and no structural or cellular abnormalities in 
histological sections, and the silica coating is easy to functionalize with organic groups, 
displaying great potential for clinical MRI.  
Experimental 
Reagents, cells and animals 
All reagents were purchased from Sigma-Aldrich, except for Gd(NO3)3.6H2O, (3-
cyanopropyl)trimethoxysilane (CPTMS) (ABCR), tetramethyl orthosilicate (TMOS) 
(MERCK), 2,5,8,11-Tetraoxatetradecan-14-oic acid succinimidyl ester (PEG3) (Iris 
Biotech) and HPLC grade solvents (Scharlab).  
HeLa cell line, 3T3 (fibroblasts cells), 42-MG-BA (glioblastoma multiforme cells) and SH-





and Cell Cultures, Braunschweig, Germany. Reagents used for cells growth were MEM 
(Earle’s), RPMI Medium 1640, DMEM and Ham (F12) Nut MIX (Gibco BRL-Life 
Technologies, CA, USA) fetal bovine serum (FBS) and penicillin/streptomycin solution 
(Pen-Strep). Dimethyl sulfoxide (DMSO) and 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazoliumbromide (MTT) were purchased from Sigma-Aldrich (St. Louis, MO, 
USA).  
Male Sprague-Dawley rats (250–300 g) (3 specimens) were acquired from Janvier Labs 
(France) and maintained under a 12/12 h light/dark cycle (lights on 07:00–19:00 h) at room 
temperature (22 ± 2°C), with free access to food and water. Rats were housed in group and 
adapted to these conditions for at least 1 week before experimental manipulation. All 
experiments were approved by the local authorities (Consejo Superior de Investigaciones 
Científicas-Universidad Miguel Hernández) and were performed in accordance with 
Spanish (law 32/2007) and European regulations (EU directive 86/609, EU decree 2001-
486). 
Stable, Gd-Fe containing, magnetic nanoparticles were synthesized in a two-step process. 
Initially, paramagnetic Gd3+ and superparamagnetic Fe3+ centers were combined in the 
structure of the PB analog Gd(H2O)4[Fe(CN)6] (GF). Here, we controlled the resulting 
hybrid shape and size by means of varying incorporation of acetic acid, obtaining uniform, 
monodispersed nanorods of about 100 nm average diameter (GF-1, no acetic acid) or a 
mixture of monodispersed nanocrosses and nanorods of 230 nm average diameter (GF-2, 
with acetic acid). Subsequently, isolated GF crystallites were coated with a thin silica layer 
by polymerization of TMOS at neutral pH in the presence of silicatein α analogues (e.g., 





pristine PB analog (respectively, GFS-1 and GFS-2). The sequence to obtain the different 
GFS samples is presented in Fig. 1. For the sake of comparison, we have included the 
alternative route corresponding to silicate polymerization over GF particles in alkaline 
medium, to give nanoparticles of Gd(OH)3.3SiO2.xH2O composite.27,28  
Finally, for in vivo studies, GFS samples were silanized with 3-aminopropyltriethoxysilane 
(APTES) and further reacted with PEG3 precursor to develop a PEG-decorated surface Gd-
PB analog (GFS@PEG). An artistic representation of the final GFS-1@PEG material is 
presented in Fig. 1 inset. 
Material synthesis 
Synthesis of Gd(H2O)4[Fe(CN)6]. (Et4N)3[Fe(CN)6] precursor was prepared according to 
a known recipe.30 Briefly, 3.3 g (10 mmol) of K3[Fe(CN)6] and 6.3 g (30 mmol) of Et4NBr 
were dissolved with 200 mL of methanol in a 500 mL flask connected to a nitrogen line, 
and stirred at 30° C for 3 days under N2 atmosphere. The mixture was filtered off and the 
filtrate was concentrated to approximately 10 mL by rotary evaporation. Resulting solution 
was stirred with 100 mL of ethyl ether and the yellow precipitate was collected by filtration. 
The crude was dissolved in 150 mL of refluxing acetonitrile and the solution was allowed 
to cool, obtaining (Et4N)3[Fe(CN)6]. For nanosized PB analog preparation, Gd(NO3)3.6H2O 
(0.75 g, 1.7 mmol) were dissolved in 50 mL of ethanol:water (EtOH:H2O) mixture (2.5:1 
v/v). Then, a solution of the previously synthesized (Et4N)3[Fe(CN)6] (1.0 g, 1.7 mmol, in 
25 mL methanol) was added and the mixture was left a day at room temperature. The 
precipitate was filtered off, washed with ethanol and vacuum dried to yield 62 mg of an 





(7.82 g, 235 mmol) were dissolved in 50 mL of EtOH:H2O (2.5:1 v/v),30 and the synthesis 
was completed as described to give 82 mg of GF-2. 
Synthesis of Gd(H2O)4[Fe(CN)6]@SiO2. Silica coated GF samples were prepared by 
adding CPTMS (417 µL, 2.19 mmol) to GF suspension (441 mg GF, 1 mmol, in 221 mL of 
EtOH:H2O mixture, 2.5:1 v/v) with vigorous magnetic stirring, to make vitreophilic GF 
surface. After 30 minutes, 1.1 mL of TMOS (7.29 mmol) and 44 µL (0.31 mmol) of TEA 
were slowly added, to adjust pH 7. The resulting dispersion was allowed to stir for 24 h at 
room temperature. Afterwards, a second equal addition of TMOS was carried out and the 
mixture was stirred for another 24 h. Finally, non-reacted silicate ions were thoroughly 
removed by subsequent centrifugation (484 g, 2 h), and the obtained orange solid was 
washed five times with EtOH:H2O mixture (2.5:1 v/v), and further freeze dried (-55 ºC, 16 
h). 
Synthesis of Gd(H2O)4[Fe(CN)6]@SiO2@PEG3. PEGylation over GFS material was done 
by using a method previously described by our group.31 331 mg of GFS was dried at 80 ºC 
and vacuum (8 torr) for 24 h. Then, 13.30 mL of anhydrous toluene was added and the 
mixture was heated to reflux. 646 µL (2.78 mmol) of 3-aminopropyltriethoxysilane 
(APTES) was added and the mixture was stirred for 3 h. The obtained product was filtered 
off, washed with toluene and methanol and freeze-dried (-55 ºC, 16h). Subsequenty, 285 
mg of the silanized material were suspended in 28.5 mL of anhydrous dichlorometane, and 
356 µL of diisopropyl amine were injected under nitrogen atmosphere. Afterwards, 221 mg 
of PEG3 were added, and the mixture was stirred overnight at room temperature. The solvent 





with stirring. This suspension was filtered off and washed with ethanol (300 mL). Finally, 
the material was freeze-dried (-55 ºC, 16 h).  
Material characterization 
Powder X-ray diffraction (XRD) patterns were collected in a Philips X’Pert diffractometer 
equipped with a graphite monochromator, operating at 40 kV and 45 mA and using nickel-
filtered Cu Kα radiation λ = 0.1542 nm). Liquid nitrogen adsorption isotherms of 200 mg 
of sample were measured in a Micromeritics Flowsorb apparatus. Surface area calculations 
were done by the BET method. Infrared spectra were recorded at room temperature in the 
400−3900 cm−1 region with a Nicolet 205xB spectrophotometer, equipped with a Data 
Station, at a spectral resolution of 1 cm−1 and accumulations of 128 scans. Samples for 
transmission electron microscopy (TEM) were ultrasonically dispersed in a mixture 
EtOH:H2O (2.5:1 v/v) and transferred to carbon coated copper grids. TEM micrographs 
were collected in a JEOL JEM 2100F microscope operating at 200 kV. The quantitative 
EDS analysis was performed in an INCA Energy TEM 250 system from Oxford 
Instruments, working with a SDD X-MAX 80 detector. Field-emission scanning electron 
microscopy (FESEM) micrographs were collected in a ZEISS Ultra 55 microscope 
operating at 2 kV, with a 2 × 10−9 A beam current and 2.5 mm as the working distance. 
Particle size and Z-Potential measurements were conducted by diffuse light scattering 
(DLS) in a Zetasizer Nano ZS (Malvern Instruments Ltd., Worcestershire, UK). Dried 
material was re-suspended at a concentration of 5 µg/mL in deionized water or phosphate 
buffer saline (PBS) and measurements were performed at 25 ºC. The mean hydrodynamic 





material were calculated from elemental analysis (FISONS, EA 1108 CHNS-O) and 
thermogravimetric (TGA) measurements (Mettler-Toledo TGA/SDTA851e).  
GFS@PEG material stability in isotonic medium was monitored by dialysis solution assay 
in aqueous glucose (5.0 wt%) and simulated body fluid (SBF).32 11 mg of the corresponding 
material were introduced in a dialysis tubing with 2 mL of glucose solution. Then, filled 
dialysis tubing was inserted in a glass bottle with 50 mL of fresh solution, and the system 
was stirred at 90 rpm and 37°C in a thermostatic bath for seven days, changing the bottle 
solution by fresh solution at the corresponding sample time. Subsequently, leached Fe3+ 
concentration was analyzed by inducted couple plasma (ICP, Varian 715-ES) or inducted 
couple plasma mass spectrometry (Varian 820-MS).  
Relaxivity measurements and in vitro MRI 
Relaxivity determinations were carried out in a clinical Phillips 3 T MRI unit (Achieva 3 T 
X-Series; Philips Healthcare, The Netherlands) using a 8-channel phased array head coil, 
and in a Bruker 9.4 T spectrometer (AV400) working with a 90º pulse of 5 µs and a recycle 
delay of 5 s. T1 and T2 relaxation times were measured using inversion recovery and cpmg 
pulse sequences respectively. For the in vitro MRI study (Philips Achieva 3 T X-Series), 
the phantom was scanned with single slice in coronal orientation obtaining transversal view 
of all tubes filled with variable CA concentration in a xantham gum solution (0.1 wt%). 
Geometric parameters remain equivalent between T2 and T1 estimation sequence (Field of 
View –FOV- 220x220 mm2, slice thickness 5 mm and 1.0 x 1.0 mm2 in plane resolution) 
sharing the same spatial localization. Multi-echo spin echo sequence was used to estimate 





Time (TR) of 2000 ms. T1 values of each tube were estimated using a look-locker inversion 
recovery acquisition with 107 inversion times ranging from 6.51-5306.51 ms, with an 
inversion time interval of 50 ms. A new inversion pulse was applied every 6 s to avoid signal 
saturation due to extremely close inversion pulses. To reduce the influence of readout 
excitation pulse in the final T1 values, an excitation flip angle of 5º was applied during the 
TFE shot.33 T2 maps were generated by a pixel by pixel nonlinear fitting of the signal 
acquired at every Echo Time (TE) to a mono-exponential model. T1 maps were generated 
by pixel by pixel nonlinear fitting of the signal acquired at every inversion time to the signal 
model of ref. 30. Quantitative values were obtained in aqueous xanthan gum (0.1 %) 
nanoparticle suspensions. For each tube, a circular ROI was placed manually over T2 and T1 
maps avoiding the border. For each ROI, mean and standard deviation were computed for 
further comparison.  
The resulting T1 and T1 values were averaged and plotted as 1/Ti (s-1) where i =1, 2 against 
the experimentally calculated metal concentration (mM), [Gd3+] for T1 and [Fe3+] for T2. 
The slopes of these graphs provided the specific relaxivities r1 and r2.  
Cytotoxicity assay 
The different cell lines were cultured in 96-well cell culture plates with the seeding densities 
shown below in a final medium volume of 200 µL/mL: HeLa 10000 cells/well; 3T3 and 42-
MGBA 50000 cells/well and SH-SY5Y 100000 cells/well. HeLa cells were grown in MEM 
(Earle’s), 3T3 cell line in DMEM, 42-MGBA cell line in MEM (Earle’s) and RPMI 1640 
(1:1), and SH-SY5Y cell line was cultured in a DMEM and Ham (F12) Nut MIX (1:1). Cell 





cultured 24 h at 37 ºC and 5% CO2 injection in air. After 24 h cells were treated with variable 
concentrations of the CA (0.25-100 µg/mL in RPMI medium). Culture medium was used 
as negative control. Cells were incubated in 5% CO2 at 37ºC for 24 h.  
Cell viability was measured using the 3-(4,5-dimethylthiazol-2-yl-diphenyltetrazolium 
bromide) (MTT) assay. 200 µL/well of MTT/PBS (1 mg/mL) were added and the plates 
were incubated at 37 ºC for 3 h. Formazan crystals were dissolved with 100 µL DMSO and 
then absorbance at 595 nm was measured with a 1681130 iMarkTM Microplate Reader. 
Absorbance values were normalized with respect to the controls and expressed in percentage 
using the next equation: 
𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅 𝑐𝑐𝑅𝑅𝑅𝑅𝑅𝑅 𝑅𝑅𝑅𝑅𝑅𝑅𝑣𝑣𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑣𝑣 =  𝑂𝑂𝑂𝑂595 𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑇𝑇𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑇𝑇
𝑂𝑂𝑂𝑂595 𝐶𝐶𝐶𝐶𝐶𝐶𝑇𝑇𝐶𝐶𝐶𝐶𝑆𝑆 ∗ 100 
Data statistical analysis was performed applying arithmetic means and error bars of 
statistical error means (SEM) using Matlab (MathWorks). IC50 calculation survival data 
were calculated by nonlinear regression sigmoidal dose–response (variable slope) curve-
fitting using Prism 6.0 software (GraphPad, San Diego, CA). At least three independent 
experiments were performed for every sample, and each experiment was carried out by 
triplicate. 
In vivo MRI study 
Experiments were carried out in a horizontal Bruker 7 T scanner with a 30 cm diameter bore 
(Biospec 70/30v, Bruker Medical, Ettlingen, Germany). The system had a 675 mT/m 
actively shielded gradient coil (Bruker, BGA 12-S) of 11.4 cm inner diameter. A 1H rat body 
receive-transmitter resonator (Bruker BioSpin MRI GmbH, Germany) was employed. Data 





Medical GmbH, Ettlingen, Germany) operating on a Linux platform. Rats were anesthetized 
in an induction chamber with 3-4% isofluorane in medical air (0.8-1 L/min) and maintained 
with 1-2 % isofluorane (IsoFlo) during the MRI experiment. Anesthetized animals were 
taped down in a custom-made animal holder to minimize breathing-related movement 
artifacts. Body temperature was kept at 37 ºC using water blanket and animals were 
monitored using a MRI compatible temperature control unit (MultiSens Signal conditioner, 
OpSens, Quebec, Canada). Breathing rate was also measured using a customized device.  
Studies were performed by injecting 1 mL of the CA suspension (5 mg mL-1) into the 
catheterized tail vein as a single bolus (0.05 mmol Gd/kg body weight, 0.05 mmol Fe/kg 
body weight). T2 weighted anatomical images to position the animal were collected in the 
three orthogonal orientations using a rapid acquisition relaxation enhanced sequence 
(RARE), applying the following parameters: FOV 40 x 40 mm, 15 slices, slice thickness 1 
mm, matrix 256 x 256, effective TE (TEeff) 56 ms, TR 2 s, 1 average and a total acquisition 
time of 64s.34,35 Two types of images were used to assess the effect of CA in the SI in T1 
and T2 weighted images. For the former, FLASH images were acquired with the following 
parameters: 25 slices, 1.5 mm slice thickness, TR 197 ms; TE 2.7 ms; FOV 6.0x5.0 cm; 
matrix 128x108; 4 averages; total acquisition time 90 s. Three images were acquired before 
CA administration (baseline) and 20 after it. For the T2 weighted images, RARE sequence 
was used with the same geometry than T1 weighted images and the following parameters: 
TR 2800 ms; TE 48 ms; FOV 6.0x5.0 cm; Mtx 256x214; 8 averages; total acquisition time 
600 s. One of these images was acquired at the beginning (baseline) and one at the end of 
the experiment. Data were analyzed with Image J (W. S. Rasband, U.S. National Institutes 





Pathological investigation after MRI 
After in vivo MRI experiments, rats were euthanized and samples of lung, heart, liver and 
spleen were collected for subsequent histological analysis. These organs were immersed in 
4% parafolmaldehyde for 24-48 h. Tissues were then included in paraffin and cut with a 
microtome 5-7 µm thickness slices. Finally, these sections were deparaffinized and stained 
with Hematoxylin/Eosin staining. Histology images were taken using Olympus AX70 
microscope. 
Results and discussion 
Synthesis and characterization of stable Gd-Fe based magnetic nanoparticles 
The strategy to obtain GFS hybrids is comparatively depicted in Fig. 1. As commented, in 
this synthesis scheme there are two crucial points to be accomplished: i) the role of acetic 
acid in shape and size distribution; and ii) an accurate pH control during silicate 
polymerization. Gd(H2O)4[Fe(CN)6] nanocrystals with well-defined morphology can be 
obtained with dual shape (e.g., crosses and rods, with an average diameter over 260 nm, and 
shape ratio of about 1:2, as determined by TEM) or like single nanorods (over 95 nm average 
diameter) (Table S1 in Supplementary Information). A possible mechanism for nanocrosses 
formation indicates that Et4N+ works as a cationic surfactant, cooperating in the synthesis 
with acetic acid to function as a soft template that forces Fe-CN-Gd crystals to assemble in 
the cross morphology.36 Actually, in the absence of carboxylic acid, only small and uniform 
rods grow.  
On the other hand, the obtained GF compound is partially soluble in water, but is stable in 





sodium silicate (pH>8.5), an ion exchange reaction takes place, resulting in complete GF 
dissolution and concurrent Gd(OH3) precipitation. By overlapping this process with  
 
Fig. 1. Sequence of the stepwise biomimetic strategy followed to obtain GFS materials and 
alternative synthetic routes. The inset shows an artistic representation of final GFS-1@PEG 
nanoparticles. 
 
silicate hydrolysis and condensation, a simultaneous and stoichiometric condensation of 
Gd(OH)3 and SiO2 takes place, yielding the nanocomposite Gd(OH)3·3SiO2·xH2O (Fig. 
1).27,28 Conversely, under neutral pH obtained by a biomimetic synthetic strategy that takes 
advantage of silicatein α functional analogues as TEA, silica wall grows homogeneously 
over CPTMS-functionalized GF nanoparticles, to give GFS material. No significant GF 
compound solution is observed during the coating process (iron leaching quickly stains the 
Gd3+/HOAc
Gd(H2O)4[Fe(CN)6] (GF-2)
(Dp ~ 220 nm)
Gd(H2O)4[Fe(CN)6] (GF-1)
(Dp ~ 100 nm)
 

























medium in yellow), resulting in Gd(H2O)4[Fe(CN)6]@SiO2 particles with same morphology 
and similar size distribution than pre-formed PB analog crystals. At this point, a slight 
increase in particle average diameter is observed in the case of GFS-1 sample small rods. 
However, GFS-2 suffers some particle size reduction after silica coating, which may be 
attributed to partial destruction of some bigger nanocrosses during the treatment (as 
confirmed by the drop in crosses/rods ratio, see Table S1 in Supplementary Information).  
These silica protected nanoparticles are expected to be stable in aqueous medium, in 
agreement with a Z-Potential lower than -10 mV (Table S1 in Supplementary Information). 
Nevertheless, DLS hydrodynamic diameter of GFS samples in water (GFS-1=124.7±81.9, 
GFS-2=343.7±154.1) is significantly larger than TEM measurements (GFS-1=106.7±33.5, 
GFS-2=230.3±35.5) (Fig. S1 in Supplementary Information), which is due to some particle 
aggregation in water, with the polydispersity index (PdI) varying from 0.2 to 0.4 (Table S1). 
In addition, the stability in PBS is clearly compromised by the high ionic strength of this 
medium, leading to very unstable suspensions were aggregation takes place in large 
extension (PdI=1, Table S1). This is notably overcome by PEGylating the samples (0.05-
0.06 mmol PEG3/g, as determined by TGA). Obtained DLS hydrodynamic diameters for 
GFS@PEG samples (GFS-1@PEG=111.4±62.7, GFS-2@PEG=228.9±79.3) are very 
similar to real size determined by TEM (Fig. S1), and PdI values are clearly lower than GFS 
suspensions (Table S1). Moreover, PEGylation significantly reduces aggregation in PBS 
(although does not fully suppress it), allowing to prepare reasonably stable suspensions of 
these nanoparticles. Besides, PEGylation contributes to minimize the immunogenic reaction 





Powder X-Ray reports reveal that GF structure is fully retained after the silica coating 
process (Fig. S2 in Supplementary Information). Also, the final PEGylation step does not 
involve any significant change in the XRD pattern. Gd(H2O)4[Fe(CN)6] crystallizes in the 
orthorhombic system with Cmcm space group and cell parameter of a = 7.4016(3) Å, b = 
12.78813(14) Å, and c = 13.5980(12) Å. In addition, it is remarkable that the nanosized 
material XRD patterns are fully comparable to that of the bulk compound.23 
Electronic microscopy study (Fig. 2) confirms the formation of monodispersed 
nanoparticles with a thin (6-10 nm width), continuous and homogenous silica shell over 
Gd(H2O)4[Fe(CN)6] core. EDS analysis is consistent with the expected PB analog 
stoichiometry (Gd:Fe atomic ratio = 1), although there are small deviations that we attribute 
to the accuracy of the analytical technique over single nanoparticles. Moreover, the spatial 
distribution of Si, Gd and Fe in isolated particles can be observed by elemental mapping 
(Fig. 2i-l), which illustrates the homogeneous distribution of Gd and Fe in the core, as well 
as the solely presence of Si at the shell. This can be clearly stated in Fig. 2d, which shows 
EDS line scans corresponding to the different elements present inwards (Gd, Fe) and 
outwards (Si) . In addition, no change is observed in the closely packed structure of the PB 
analog and estimation of interplanar distance over the [112] plane by TEM matches 
reasonably well the theoretical calculation from Bragg’s law (Fig. 2g-h). 
FTIR reports display two peaks at 2140 and 2150 cm-1 corresponding to stretching vibration 
of Fe-CN-Gd bond, and an additional st vibration at 2070 cm-1 (Fig. S3 in Supplementary 
Information). The low energy signal is originated from ferrocyanide [Fe(CN)6]4-, which is 






Fig. 2. Electron microscopy study of as-synthesized GFS materials. (a,b): GFS-1 sample 
general images by TEM (a) and FESEM (b). (c) High resolution TEM image of a GFS-1 
nanorod showing its core-shell nature. The inset shows an artistic representation. (d) EDS 
line scans of a GFS-1 nanorod depict the changes in composition from particle outer surface 
to the inner core. (e) GFS-2 sample general image by STEM. (f) High resolution TEM image 
of GFS-2 nanocross showing its core-shell nature. A magnification of this picture in (g) 
allows to observe the PB analogue closely packed structure at the [112] plane. Also, 
interplanar distance calculation by TEM over 10 sheets (h) matches quiet good the 
theoretical calculation from the Bragg’s law. (i-l) EDS elemental mapping pictures of a 
GFS-2 nanocross. 
 
Small peaks in the range 1610-1630 cm-1 are assigned to δ (H-O-H) vibration.37 Conversely, 
a sharp ν (H-O) signal is present at 3610 cm-1 and an intense broad band ν (H-O-H) is 
observed in the range 3000-3550 cm-1.37,38 After endowing the GF particles with the silica 
coating, a new broad signal centered at 1085 cm-1 appears, corresponding to ν (Si-O-Si) 
vibration. In addition, PEGylated samples show small peaks in the range 2850-2950 cm-1, 
which are due to ν (C-H) of methylene groups. 





























The silica coating reveals itself crucial for the stability of these hybrids in physiological 
fluids. GF material is partially soluble in water and physiological fluids, leaching significant 
quantities of metal cations over a short period. To study this we dispersed GFS-1@PEG at 
37 ºC in isotonic glucose 5 wt% medium or in SBF and monitored the leached metal 
concentration by ICP/ICP-MS (Fig. S4 in Supplementary Information). Unfortunately, in 
these testing conditions, most of the released Gd3+ is quickly precipitated as Gd(OH)3·xH2O, 
remaining in the dialysis bag as a white powder, so the obtained Gd3+ concentration in 
dialysis samples is very low and can’t be used as a pattern of metal leaching (total 
Gd3+quantity measured in solution by ICP-MS was lower than 0.5 %). In this context, Fig. 
S4 in Supplementary Information shows only Fe3+ leaching in glucose 5% solution (as 
determined by ICP) and in SBF (as determined by ICP-MS). We observed negligible metal 
leaching in the first 4 h (<1 %) and about 5-11 % at 24 h, which makes this material suitable 
for in vivo MRI (image acquisition takes place no longer than 1-2 hours after iv 
administration). Furthermore, even after 7 days, the concentration of leached metals was 
lower than 25% in both mediums. This is also important, as it implies very slow particle 
degradation, which should allow almost complete particle elimination by renal and biliary 
routes before reaching toxicity.39 
It is noticeable that the coating process is determinant not only to prevent PB analog solution 
in aqueous medium, but also to increase hybrid surface area, as the highly packed Gd-Fe 
structure is difficult to functionalize with organic ligands. In this sense, the adsorption 
pattern obtained from the nitrogen isotherms over silica covered samples correspond to 





and Fig. S5 in Supplementary Information). This is enough for subsequent incorporation of 
different functionalities, as therapeutic agents, targeting compounds and/or PEG molecules. 
Relaxivity measurements and in vitro MRI 
The efficacy of GFS material as T1- and T2 MRI CA was evaluated by measuring the 
longitudinal (r1) and transversal (r2) nuclear magnetic relaxation rates of water proton in 
aqueous suspensions at room temperature and magnetic field of 3 T and 9.4 T. Stable 
colloids were prepared in aqueous xantham gum (0.1 wt%) solution with M3+ concentration 
in the range 0-1.00 mM (Gd3+ for T1, Fe3+ for T2). Relaxivity values were determined by 
using the following expression:40 
 
Where i = 1 or 2 values, respectively, for longitudinal or transversal-weighted effect of CA. 
1/Ti(w) is the global relaxation rate constant of bulk water molecules, Ti(0) is the water 
relaxation time without CA, and C is the paramagnetic ion concentration. r1 and r2 values 
were determined, respectively, from the slopes of 1/T1 (s-1) and 1/T2 (s-1) versus M3+ 
concentration (Table 1 and Fig. S6 in Supplementary Information). For the sake of 
comparison, same measurements were carried out with commercial CA gadopentetate 
dihydrogen salt (Gd-DPTA, Sigma-Aldrich).  
GFS-1 and GFS-2 show high r1 and r2 values at high magnetic field (9.4 T), of about 1 order 














B0=9.4 (T)    
Gd-DTPA 4.4 4.6 1.04 
GFS-1 13.1 66.6 5.1 
GFS-2 11.7 58.6 5.0 
GFS-1@PEG 20.8 69.9 3.4 
GFS-2@PEG 16.7 59.6 3.6 
B0=3.0(T)    
Gd-DTPA 3.8 3.0 0.8 
GFS-1@PEG 27.0 35.1 1.3 
 
A dramatic T2 reduction is expected with regards to the commercial chelate due to the 
presence of a huge population of Fe3+ centers in GFS samples. However, the increased r1 
value compared to mononuclear species of Gd3+ is mostly due to the spin order of Gd3+ runs 
parallel to the local magnetic field induced by the superparamagnetic Fe3+ center domains 
under an external magnetic field.17 Also, the partial contribution of T1 shortening by Fe3+ 
sites may enhance T1 contrast effect. This synergistic effect is possible by the extremely 
dense Gd3+ and Fe3+ ion packaging at the same crystalline structure, which are connected 
via cyano-bridge bonds.23 Actually, a perspective view of the network topology of GF 
structure at Fig. 3 shows two different Gd-Fe non-bonding distances, estimated as 5.509 and 
5.352 Å. A similar synergistic effect has been observed when embedding Gd oxide 






Fig. 3. (a) Perspective view of the network topology of Gd(H2O)4[Fe(CN)6], where water 
molecules have been removed. Gd, is at the center of the green triangular prisms; and Fe is 
at the center of the octahedra. When water is considered, two water molecules coordinate to 
each Gd atom giving a square anti-prism coordination for Gd. (b) Perspective view of the 
structure and coordination of a Gd atom in the Gd(H2O)4[Fe(CN)6] structure. Two water 
molecules have been omitted for clarity. Two different non-bonding distances Gd-Fe 
appear, 5.509 Å (4) and 5.352 Å (2). 
 
At this point, we are aware of the fact that the external silica coating could be an issue over 
the magnetic properties of GFS samples, mostly over longitudinal relaxation. According to 
Solomon-Bloembergen-Morgan theory, T1 shortening is related to directly bound water 
molecule interactions over magnetic centers, corresponding to the inner sphere relaxation 
mechanism.7,8 This interaction is hindered in nanoparticles fully covered with an 
homogeneous and non-porous silica shell. However, contrast agents can display relaxivity 
even when there is no water in the inner coordination sphere, and in this case the relaxivity 
comes from outer sphere contributions, where water molecules hydrogen bonded to silica 
surface are relaxed via dipolar mechanisms.42 
Moreover, r1 gain is clearly higher for PEGylated samples (of about 60% for GFS-1 and 
45% for GFS-2, Table 1). As T1 shortening is mainly related to the chemical exchange of 
protons with M3+ centers at the water sphere regime, it should improve when particle 






colloid by reducing particle aggregation and hydrodynamic diameter (Table S1 and Fig. S1 
at the Supplementary Information), which promotes surface interaction with water 
molecules. Here, other authors have reported the strong effect of PEGylation over water 
exchange and water molecule access to Gd3+ centers, and its influence over longitudinal 
relaxivity.43 Conversely, PEGylation shows a modest effect over transversal relaxivity (a 
very short increase of 2-4% at B0= 9.4 T, Table 1), as r2 is little dependent on metal ion 
hydration, mean residence time of the water molecule in the first coordination sphere, and 
the tumbling rate of the species.  
In the same line, the modest r1 increase in GFS-1 and GFS-1@PEG hybrids with regards, 
respectively, to GFS-2 and GFS-2@PEG samples is assumed as consequence of the smaller 
particle size.44 Such effect is even stronger at lower magnetic field intensity (3 T), with the 
r2/r1 ratio getting close to 1 (GFS-1@PEG sample, Table 1). This, together with a relatively 
high r2 value prompt the use of GFS material as T1-T2 dual-modal MRI CA.  
To further check this capability, phantom MRI images with GFS-1@PEG sample (Fig. 4) 
were collected. For the purpose of comparison, two regular T1-agents, commercial Gd-
DPTA chelate (r1 = 4.1 mM-1 s-1, r2 = 3.3 mM-1 s-1) and Gd-Si oxide nanoparticles (GdSi, 
r1 = 5.6 mM-1 s-1, r2 = 8.2 mM-1 s-1),28 were also tested. The phantoms were scanned with a 
single slice in coronal orientation. Fig. 4a shows the T1-weighted images of the different 
materials at variable CA concentration based on Gd3+ content. Both GdSi and Gd-DPTA 
display a similar signal enhancement depending on concentration. However, GFS-1@PEG 
presents a much stronger contrast effect, due to the described synergistic effect between 
Gd3+ and Fe3+ magnetic centers. Such differences are stressed in a T1-weighted image of a 





4c presents the T2-weighted images corresponding to these samples at variable M3+ 
concentration (Gd3+ for GdSi and Gd-DTPA, Fe3+ for GFS-1@PEG). As expected, the GFS 
hybrid exhibits superior dark contrast performance due to the presence of Fe3+ 
superparamagnetic centers. 
 
Fig. 4. Phantom MRI images of GFS-1 sample and two regular T1-agents, commercial Gd-
DTPA and Gd-Si oxide nanoparticles (GdSi).28 (a) T1-weighted MRI coronal slices at 
magnetic field of 3 T and echo time of 2 ms over varying Gd3+ concentration. (b) T1-
weighted MRI transversal slice at magnetic field of 3 T and echo time of 2 ms over Gd3+=1 
mM. (c) T2-weighted MRI slices at magnetic field of 3 T and echo time of 203 ms over 
varying M3+ concentration (Gd3+ for GdSi and Gd-DTPA, Fe3+ for GFS-1). 
 
Cytotoxicity study 
To validate GFS nanoparticle potential performance in a biological environment, cell 
viability was assessed 24 h after incubation with the GFS-1 sample by determination of 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) conversion to its 
formazan form, by following standard procedures. We used healthy fibroblasts (3T3 cell 
line) and three different cancer cell lines (HeLa cells, 42-MG-BA glioblastoma multiforme 
cells and SH-SY5Y neuroblastoma cells) at a range of concentrations (0.25-100 µg mL-1). 
Results (Fig. S7 in Supplementary Information) indicate that even at the highest particle 
loading, relative cell viability was above 70%. Actually, despite MTT testing inherent 
limitations for accurate cell viability determination, these results correspond to an 
acceptable biocompatibility profile.45 
GdSi
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In vivo dual T1 and T2-weighted MRI 
Direct iv administration of GFS-1 nanoparticles is precluded due to the immediate and 
strong reaction with serum proteins, which results in protein corona formation. This 
promotes subsequent interaction with cell elements of the reticuloendothelial system, and 
rapid particle clearance from blood, which are accumulated mostly in liver, spleen and 
lungs.46 In order to minimize this non-specific immunogenic process, GFS-1 nanorods were 
modified with a short PEG chain, according to a known recipe,31 to give GFS-1@PEG. This 
way, nanoparticles are expected to prolong their blood circulation time, finally being 
eliminated mainly by renal (urine) and hepatic (biliary) routes.38,47 Subsequently, 1 mL of a 
5 mg mL-1 GFS-1@PEG stable colloid in glucose 5% was perfused into the catheterized tail 
vein of healthy male Sprague-Dawley rats as a bolus (~0.05 mmol Gd kg-1 and 0.05 mmol 
Fe kg-1). After 30 min, T1- and T2-weighted images were acquired for 1 h by using a 7 T 
horizontal scanner. Previously to CA administration images, baseline images were 
processed.  
Fig. 5 shows coronal T1- and T2-weighted MRI before (baseline) and after CA. For the sake 
of clarity, the different regions of interest (ROIs) presenting the most significant signal to 
noise ratio (SNR) changes have been manually labeled over pre-injection images. SNR 
changes are compiled in Table 2. T1-weighted images show clear positive signal 
enhancement in liver (∆SNR = 17.3 % relative to baseline, Fig. 5a,a’) and kidneys (∆SNR 
= 6.4 %, Fig. 5c,c’). This is not surprising as these organs receive most of the blood stream, 
which favors highly promoted particle accumulation. Despite its large size and lobular 
shape, liver presented mostly uniform changes in SI, which corresponds to a homogeneous 





strong negative contrast for liver (∆SNR = 27.8%, Fig. 5b,b’), gallbladder (∆SNR = 78.0%, 
Fig. 5b,b’) and kidneys (∆SNR = 51.7%, Fig. 5d,d’). In all cases, the contrast enhancement 
remains fully stable during the whole acquisition time (1 h), although a significant extension 
of acquisition period should be feasible.  
Table 2 Magnitude of the normalized changes in the signal to noise ratio (SNR) of T1- and 
T2 weighted images after iv administration of GFS-1@PEG in a Sprague-Dawley rat (0.05 
mmol Gd Kg-1 and 0.05 mmol Fe Kg-1). Values correspond to mean ∆SNR averaged over 
15 min after the injection. 
Region of Interest ∆SNR 
(%) 
T1-weighted images  
Liver 17.3 
Gallbladder  0.1 
Paraspinous muscle  3.0 
Kidney  6.4 
T2-weighted images  
Liver 27.8 
Gallbladder 78.0 
Paraspinous muscle   6.3 
Kidney 51.7 
 
Furthermore, no structural or cellular abnormalities were detected in lung, heart, spleen and 
liver slices of treated animals. Fig. 6 shows some representative examples of histological 
sections in a CA administered rat (Fig. 6a-h) and the same histological plates for a non-






Fig. 5. In vivo coronal T1- and T2-weighted images acquired from a male Sprague-Dawley 
rat at 7 T magnetic field. (a-j) Control (baseline) with no MNP administration. The 
following ROIs have been manually labeled (red lines): 1-liver; 2-gallblader; 3-paraspinous 
muscle; 4-kidney; 5-stomach; 6-pancreas. (a’-j’) Acquisition 30 min after GFS-1@PEG 
nanorod injection (0.05 mmol Gd3+ kg-1, 0.05 mmol Fe3+ kg-1). 
 
Liver histology (Fig. 6a,b and 6i,j) does not display haemorrhages in hepatic vein and 
arteries, neither shows damage or abnormalities in the liver lobules cells or structure. No 
abnormities were seen in spleen histology (Fig. 6c,d and 6k,l) in the white and the red pulp. 
Lymph nodes structure was normal and no signs of haemorrhages or high immune system 

























































Also, heart myocardium histology was not been affected by the CA (Fig. 6e,f and 6m,n). 
Regarding pericardium and endocardium, both structures were kept intact after agent 
contrast administration (images not shown). Finally, lung histological slices (Fig. 6g,h and 
6o,p) showed no pulmonary failure signs and intact alveolar and bronchial structures. 
 
Fig. 6. (a-h) Hematoxylin/eosin staining of histological slices after administration (single 
bolus) of GFS-1@PEG (0.05 mmol Gd3+ kg-1, 0.05 mmol Fe3+ kg-1). (i-p) Same histological 
slices in a control specimen.  
 
Overall, these findings indicate that PEGylated GFS material is highly biocompatible dual 
CAs able to provide both positive T1 and negative T2 contrast enhancement in MR imaging. 
This is a consequence of the GFS improved characteristics as MRI CA, presenting 








































values due to the synergistic effect between Gd3+ and Fe3+ centers in a closely packed 
crystalline structure. 
Conclusions 
The incorporation of T1 and T2 active moieties in a CA for dual-modal MRI provides 
complementary information that can help to improve the safety of diagnosis. In this sense, 
we have developed a novel hybrid material with high performance as MRI CA by 
optimizing the synthesis of Gd(H2O)4[Fe(CN)6] magnetic nanoparticles with controlled size 
and morphology, covering them with a thin diamagnetic silica layer by following a 
biomimetic strategy for silicate hydrolysis and polymerization at neutral pH. The obtained 
system shows long-term stability in physiological fluids because of the protecting non-
porous outer shell. This material presents longitudinal relaxivity values over one order 
superior to regular T1 Gd3+ based systems and much stronger positive contrast in in vitro 
and in vivo MR images, due to the synergistic effect between Gd3+ and Fe3+ magnetic centers 
closely connected via cyano-bridge bonds in a highly packed crystalline structure. In 
addition, the GFS hybrid exhibits transversal relaxivity data comparable to that of iron oxide 
nanoparticles, which provides strong dark contrast performance in in vitro and in vivo MRI. 
The lack of cytotoxicity checked in different cell lines and the absence of histological 
damage observed in the main organs of tested animals indicate a good biosafety profile, 
stressing the potential of this CA in clinical applications. With regards other proposed T1-
T2 dual mode CAs, these nanoparticles present very homogeneous composition and constant 
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Gd and Fe centers closely packed in Gd(H2O)4[Fe(CN)6]@SiO2 network promote a 
magnetic synergistic effect, which improves longitudinal relaxivity.   
